ADVA
ADVA (FSE: ADV) today launched its OSA 5405-P substation grandmaster, an ultra-compact synchronization solution specifically designed for the digital transformation of power utility networks. The OSA 5405-P delivers the precise and reliable timing that utilities need to leverage new smart grid applications, including intelligent power generation, distribution and control systems. The solution protects mission-critical infrastructure from the risk of outages caused by loss of timing from satellite signals by combining GNSS receivers with accurate PTP grandmaster clocks and network-delivered timing. Available with rack, DIN rail and wall mounting options, the OSA 5405-P also reduces cost and complexity in synchronization networks. What’s more, by supporting both legacy and new timing technologies, the solution empowers utility networks to smoothly and cost-effectively transition to next-generation synchronization.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210311005049/en/
“The utility network landscape is changing. With the move to distributed power generation and the digital transformation of substations, utilities face a new set of challenges and opportunities. To succeed, all processes must be tightly synchronized and a new level of accurate, robust timing is required. Our OSA 5405-P addresses these exact needs and offers power network operators a simple and affordable route from legacy synchronization to fully protected and assured PTP timing,” said Gil Biran, general manager, Oscilloquartz, ADVA. “Now utility networks can leverage a solution tailored to their precise needs that’s easy to install anywhere. And with our sophisticated Ensemble Controller and Sync Director, synchronization is easy to manage and operate.”
The OSA 5405-P offers power network operators a risk-free way to migrate their existing timing infrastructure to the accurate and robust PTP timing needed for new automated technologies and smart grid applications. With network-based synchronization backing up timing from GNSS, the OSA 5405-P removes vulnerability to loss of satellite signals. It supports multiple PTP profiles, including the Power Profile, and features NTP as well as IRIG-B interfaces for precise time synchronization of all power system devices. Its Syncjack™ capabilities also deliver accurate, real-time monitoring of synchronization quality. The OSA 5405-P is the ultimate power utility synchronization solution where cost-efficiency and small footprint are key. With rack and DIN rail mounting options, it’s extremely versatile to deploy. Ideal for secondary substations, it can also complement the OSA 5422-IRIG solution in primary substations. The OSA 5405-P also utilizes in-service sync probing and assurance as well as innovative GNSS assurance capabilities.
“Smart grids need intelligent timing. That’s what our OSA 5405-P offers. It brings assured and protected synchronization to the edge of the power network in an extremely cost-efficient way. Now operators can rely on their infrastructure delivering the robust and accurate timing needed for new secondary substation and protection relay technologies,” commented Nir Laufer, VP, product line management, Oscilloquartz, ADVA. “The compact and environmentally friendly design of our solution will be especially valuable as utility networks migrate to packet-based timing. The OSA 5405-P distributes accurate timing with the smallest size and power footprint on the market. That means major savings on rack space and a significant reduction in complexity.”
Further details on the OSA 5405-P are available in these slides: https://adva.li/osa-5405-p-slides .
A supporting solution brief can be downloaded here: https://adva.li/osa-5405-p-solution-brief .
About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com
.
About Oscilloquartz
Oscilloquartz is a pioneer in time and frequency synchronization. We design, manufacture and deploy end-to-end synchronization systems that ensure the delivery and assurance of highly precise timing information over next-generation packet and legacy networks. As an ADVA company, we’re creating new opportunities for tomorrow’s networks. For more information, please visit us at www.oscilloquartz.com
.
Published by:
ADVA Optical Networking SE, Munich, Germany
www.adva.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20210311005049/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
